Immunohistochemical expression of EGFR in oral leukoplakia: Association with clinicopathological features and cellular proliferation

Medicina Oral, Patologia Oral y Cirugia Bucal

Volumn 17, Issue 5, 2012, Pages

  Ribeiro, Daniela Cotta ^a   Gleber Netto, Frederico Omar ^a   Sousa, Sílvia Ferreira ^a   Bernardes, Vanessa de Fátima ^a   Guimarães Abreu, Mauro Henrique Nogueira ^a   Aguiar, Maria Cássia Ferreira ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

EGFR; Epithelial dysplasia; Ki 67; Oral leukoplakia; p27

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; MALE; MOUTH MUCOSA; PATHOLOGY; PROTEIN EXPRESSION; STUDY DESIGN; TOBACCO;

ADULT; AGED; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA, ORAL; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 84866716190     PISSN: 16984447     EISSN: 16986946     Source Type: Journal    
DOI: 10.4317/medoral.17950     Document Type: Article

References (31)

1. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36:575-80.
2. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol. 2009;45:317-23.
3. Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med. 2008;37:127-33.
4. Dietrich T, Reichart PA, Scheifele C. Clinical risk factors of oral leukoplakia in a representative sample of the US population. Oral Oncol. 2004;40:158-63.
5. Gümüş ZH, Du B, Kacker A, Boyle JO, Bocker JM, Mukherjee P, et al. Effects of tobacco smoke on gene expression and cellular pathways in a cellular model of oral leukoplakia. Cancer Prev Res (Phila). 2008;1:100-11.
6. Zhang L, Cheung KJ Jr, Lam WL, Cheng X, Poh C, Priddy R, et al. Increased genetic damage in oral leukoplakia from high risk sites: potential impact on staging and clinical management. Cancer. 2001;91:2148-55.
7. Pitiyage G, Tilakaratne WM, Tavassoli M, Warnakulasuriya S. Molecular markers in oral epithelial dysplasia: review. J Oral Pathol Med. 2009;38:737-52.
8. O-charoenrat P, Rhys-Evans PH, Modjtahedi H, Eccles SA. The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol. 2002;38:627-40.
9. Sarkis SA, Abdullah BH, Abdul Majeed BA, Talabani NG. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma in relation to proliferation, apoptosis, angiogenesis and lymphangiogenesis. Head Neck Oncol. 2010;2:13.
10. Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, Gorgoulis VG. Advances in the biology of oral cancer. Oral Oncol. 2007;43:523-34.
11. Berlanga-Acosta J, Gavilondo-Cowley J, Lopez-Saura P, González-López T, Castro-Santana MD, López-Mola E, et al. Epidermal growth factor in clinical practice-a review of its biological actions, clinical indications and safety implications. Int Wound J. 2009;6:331-46.
12. Benchekroun MT, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, et al. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res. 2010;3:800-9.
13. Grandis JR, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res. 1998;4:13-20.
14. Nagatsuka H, Ishiwari Y, Tsujigiwa H, Nakano K, Nagai N. Quantitation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malignant oral epithelial lesions. Oral Oncol. 2001;37:599-604.
15. Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 1994;54:3153-59.
16. Djerf EA, Trinks C, Abdiu A, Thunell LK, Hallbeck AL, Walz TM. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839). Melanoma Res. 2009;19:156-166.
17. Lee EJ, Whang JH, Jeon NK, Kim J. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses proliferation and invasion of human oral squamous carcinoma cells via p53 independent and MMP, uPAR dependent mechanism. Ann N Y Acad Sci. 2007;1095:113-128.
18. Shintani S, Li C, Mihara M, Yano J, Terakado N, Nakashiro K, et al. Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines. Oral Oncol. 2004;40:43-51.
19. Diniz-Freitas M, Garcia-Caballero T, Antunez-Lopez J, Gandara-Rey JM, Garcia-Garcia A. Pharmacodiagnostic evaluation of EGFR expression in oral squamous cell carcinoma. Oral Dis. 2007;13:285-90.
20. Gonzalez-Moles MA, Ruiz-Avila I, Rodriguez-Archilla A, Martinez-Lara I. Suprabasal expression of Ki-67 antigen as a marker for the presence and severity of oral epithelial dysplasia. Head Neck. 2000;22:658-61.
21. Kovesi G, Szende B. Prognostic value of cyclin D1, p27, and p63 in oral leukoplakia. J Oral Pathol Med. 2006;35:274-77.
22. Srinivasan M, Jewell SD. Evaluation of TGF-alpha and EGFR expression in oral leukoplakia and oral submucous fibrosis by quantitative immunohistochemistry. Oncology. 2001;61:284-92.
23. Rautava J, Jee KJ, Miettinen PJ, Nagy B, Myllykangas S, Odell EW, et al. ERBB receptors in developing, dysplastic and malignant oral epithelia. Oral Oncol. 2008;44:227-35.
24. Kan JU, Koo SH, Kwon KC, Park JW, Jung SS. Gain of the EGFR gene located on 7p12 is a frequent and early event in squamous cell carcinoma of the lung. Cancer Genet Cytogenet. 2008;184:31-7.
25. Du B, Altork NK, Kopelovich L, Subbaramaiah K, Dannenberg AJ. Tobacco smoke stimulates the transcription of amphiregulin in human oral epithelial cells: evidence of a cyclic AMP-responsive element binding protein-dependent mechanism. Cancer Res. 2005;65:5982-88.
26. Du B, Leung H, Khan KM, Miller CG, Subbaramaiah K, Falcone DJ, et al. Tobacco smoke induces urokinase-type plasminogen activator and cell invasiveness: evidence for an epidermal growth factor receptor dependent mechanism. Cancer Res. 2007;67:8966-72.
27. Liu SC, Klein-Szanto AJ. Markers of proliferation in normal and leukoplakic oral epithelia. Oral Oncol. 2000;36:145-51.
28. Takeda T, Sugihara K, Hirayama Y, Hirano M, Tanuma JI, Semba I. Immunohistological evaluation of Ki-67, p63, CK19 and p53 expression in oral epithelial dysplasias. J Oral Pathol Med. 2006;35:369-75.
29. Jordan RC, Bradley G, Slingerland J. Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity. Am J Pathol. 1998;152:585-90.
30. Tsuzuki H, Fujieda S, Sunaga H, Narita N, Tokuriki M, Saito H. Expression of p27 and apoptosis in oral leukoplakia. Anticancer Res. 2003;23:1265-70.
31. Ben-Izhak O, Kablan F, Laster Z, Nagler RM. Oropharyngeal cancer pathogenesis: ubiquitin proteolytic, apoptotic and epidermal growth factor related pathways act in concert-first report. Oral Oncol. 2005;4:851-60.